PE15197A1 - ANTI-OBESITY PROTEINS - Google Patents

ANTI-OBESITY PROTEINS

Info

Publication number
PE15197A1
PE15197A1 PE1996000072A PE00007296A PE15197A1 PE 15197 A1 PE15197 A1 PE 15197A1 PE 1996000072 A PE1996000072 A PE 1996000072A PE 00007296 A PE00007296 A PE 00007296A PE 15197 A1 PE15197 A1 PE 15197A1
Authority
PE
Peru
Prior art keywords
xaa
gln
asn
glu
leu
Prior art date
Application number
PE1996000072A
Other languages
Spanish (es)
Inventor
Richard Dennis Dimarchi
Jr William Francis Heath
Margaret Barbara Basinski
Brigitte Elisabeth Schoner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE15197A1 publication Critical patent/PE15197A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A PROTEINAS DE FORMULA GENERAL I, DONDE: Xaa EN LAS POSICIONES 4, 7, 28, 34, 56, 62, 63, 75, 130, 134 Y 139 ES GLN O GLU 0 PUEDE ESTAR AUSENTE (SOLO EN 28); Xaa EN 54, 68 Y 136 ES MET, LEU, ENTRE OTROS; Xaa EN 22 Y 72 ES ASN, ASP O GLU; Xaa EN 78 Y 82 ES GLN, ASN O ASP; Xaa EN 27 ES THR O ALA; Xaa EN 77 ES SER O ALA; Xaa EN 118 ES GLY O LEU; Y QUE TIENE COMO MINIMO UNA SUSTITUCION EN LAS POSICIONES 97, 100, 101, 102, 103, 105, 106, 107, 108, 111, 138 Y/O EXISTEN UNIONES DISULFURO ENTRE CYS EN 96 Y CIS EN 146, PARA LOGRAR MEJORAR LA ESTABILIDAD DE LA PROTEINA. TAMBIEN SE REFIERE AL PROCESO DE HACER LAS PROTEINAS DE FORMULA GENERAL I, QUE COMPRENDE: A) TRANSFORMAR UN MINERAL CON INCLUSION DE CELULAS CON DNA, QUE CODIFICA CUALQUIERA DE LAS PROTEINAS, PROVISTAS OPCIONALMENTE DE UNA SECUENCIA GUIA OPCIONAL, QUE ES MET-R1, DONDE R1 ES UN AMINOACIDO, PREFERENTEMENTE ARG, EXCEPTO PRO; B) CULTIVAR UN MINERAL CON INCLUSION DE CELULAS Y AISLAR LA PROTEINA CODIFICADA EN (A); Y OPC. C) PARTIR ENZIMATICAMENTE LA SECUENCIA LIDER. ESTAS AGENTES TERAPEUTICOS REGULAN EL TEJIDO ADIPOSO, NORMALIZANDO EL RIESGO DE DIABETES MELLITUS TIPO II, ENFERMEDADES CARDIOVASCULARES Y EL CANCERREFERS TO PROTEINS OF GENERAL FORMULA I, WHERE: Xaa IN POSITIONS 4, 7, 28, 34, 56, 62, 63, 75, 130, 134 AND 139 IS GLN OR GLU 0 MAY BE ABSENT (ONLY IN 28); Xaa EN 54, 68 AND 136 IS MET, LEU, AMONG OTHERS; Xaa EN 22 and 72 IS ASN, ASP OR GLU; Xaa EN 78 and 82 IS GLN, ASN, or ASP; Xaa EN 27 IS THR OR ALA; Xaa EN 77 IS BEING OR WING; Xaa EN 118 IS GLY O LEU; AND THAT IT HAS AS A MINIMUM A SUBSTITUTION IN POSITIONS 97, 100, 101, 102, 103, 105, 106, 107, 108, 111, 138 AND / OR THERE ARE DISULFURED JOINTS BETWEEN CYS IN 96 AND CIS IN 146, TO ACHIEVE IMPROVE THE PROTEIN STABILITY. IT ALSO REFERS TO THE PROCESS OF MAKING PROTEINS FROM GENERAL FORMULA I, WHICH INCLUDES: A) TRANSFORMING A MINERAL WITH INCLUSION OF CELLS WITH DNA, WHICH CODIFIES ANY OPTIONAL GUIDE SEQUENCE, WHICH IS MET-R WHERE R1 IS AN AMINO ACID, PREFERABLY ARG, EXCEPT PRO; B) CULTIVATE A MINERAL WITH INCLUSION OF CELLS AND ISOLATE THE PROTEIN CODED IN (A); AND OPC. C) ENZYMATICALLY START THE LEADING SEQUENCE. THESE THERAPEUTIC AGENTS REGULATE THE ADIPOSE TISSUE, NORMALIZING THE RISK OF DIABETES MELLITUS TYPE II, CARDIOVASCULAR DISEASES AND CANCER

PE1996000072A 1995-01-31 1996-01-30 ANTI-OBESITY PROTEINS PE15197A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38104895A 1995-01-31 1995-01-31
US38363895A 1995-02-06 1995-02-06
US45095P 1995-06-22 1995-06-22
US216195P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
PE15197A1 true PE15197A1 (en) 1997-05-22

Family

ID=27484996

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000072A PE15197A1 (en) 1995-01-31 1996-01-30 ANTI-OBESITY PROTEINS

Country Status (15)

Country Link
JP (1) JPH10513451A (en)
KR (1) KR19980701798A (en)
AR (1) AR002956A1 (en)
AU (1) AU703316B2 (en)
BR (1) BR9606999A (en)
CA (1) CA2211784A1 (en)
CO (1) CO4480035A1 (en)
CZ (1) CZ240497A3 (en)
FI (1) FI973162A (en)
NO (1) NO973515L (en)
NZ (1) NZ301589A (en)
PE (1) PE15197A1 (en)
PL (1) PL321702A1 (en)
TR (1) TR199600085A2 (en)
YU (1) YU5296A (en)

Also Published As

Publication number Publication date
BR9606999A (en) 1997-10-28
TR199600085A2 (en) 1996-08-21
FI973162A0 (en) 1997-07-30
CA2211784A1 (en) 1996-08-08
AU703316B2 (en) 1999-03-25
NO973515L (en) 1997-09-29
YU5296A (en) 1998-08-14
NO973515D0 (en) 1997-07-30
PL321702A1 (en) 1997-12-22
AR002956A1 (en) 1998-05-27
CZ240497A3 (en) 1998-01-14
AU4705296A (en) 1996-08-21
JPH10513451A (en) 1998-12-22
FI973162A (en) 1997-09-30
NZ301589A (en) 1999-02-25
KR19980701798A (en) 1998-06-25
CO4480035A1 (en) 1997-07-09

Similar Documents

Publication Publication Date Title
Morton et al. Collagen polymorphism in the normal and diseased blood vessel wall: investigation of collagens types I, III and V
PE15297A1 (en) ANTI-OBESITY PROTEINS
Sage et al. Characterization of a novel collagen chain in human placenta and its relation to AB collagen
Craig et al. An O-glycosylated neuroexcitatory Conus peptide
Elsayed et al. The primary structure of allergen M from cod
KR960703433A (en) A TRUNCATED KERATINOCYTE GROWTH FACTOR (KGF) HAVING INCREASED BIOLOGICAL ACTIVITY With Increased Biological Activity
PT93910A (en) A product for the preparation of a blood protein by means of a blood cell
NO872932L (en) PROCEDURE FOR THE MANUFACTURE OF PROTEINS WITH FACTOR VIVILITY BY MICROBIAL HOSTS, EXPRESSING VECTORS, HOSTING CELLS, ANTIBIOTICS.
KR900013979A (en) Immunogenic Regions of the Human Papillomavirus Type 16 E7 Protein
ATE426024T1 (en) C-C CHEMOKINE RECEPTOR 3: CKR-3 OR EOS-L2
AR023099A1 (en) DNA CONSTRUCTS CODING SARATINA AND ITS USES.
KR920701451A (en) Fusion protein containing an N-terminal fragment of human serum albumin
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
WO2003104270A3 (en) Dudulin genes, non-human animal model: uses in human hematological disease
ES2161246T3 (en) TRANSFORMING FACTOR OF ALFA H1 GROWTH.
CO4790156A1 (en) MAMMALIAN LYMPHOCYTE MEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS THAT CODE THEM
Johns et al. Studies on histones. 4. The histones of wheat germ
PE50997A1 (en) PRODUCT OF THE GENE OF OBESITY
EA200100264A1 (en) ANGIOCIDIN: AN ADHESIVE CELL TUMOR RECEPTOR SPECIFIC FOR CYS-SER-VAL-THR-CYS-GLY
CN103038351A (en) Vitronectin:keratinocyte growth factor chimeras
Dey et al. Extensin from suspension-cultured potato cells: a hydroxyproline-rich glycoprotein, devoid of agglutinin activity
Mayne et al. The use of monoclonal antibodies to fragments of chicken type IV collagen in structural and localization studies.
Koike et al. The complete amino acid sequence of a mannose-binding lectin from" Kidachi Aloe"(Aloe arborescens Miller var. natalensis Berger)
HENSCHEN Disulfide bridges in the middle part of human fibrinogen
Ehrlich et al. Evidence for type V and I trimer collagens in Dupuytren's Contracture palmar fascia

Legal Events

Date Code Title Description
FD Application declared void or lapsed